New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
10:03 EDTPANW, NLNK, BIG, SWY, XOMAOptions with decreasing implied volatility: NLNK XOMA BIG PANW SWY
News For NLNK;XOMA;BIG;PANW;SWY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 22, 2015
12:32 EDTXOMAOn The Fly: Top stock stories at midday
Stocks on Wall Street were lower at midday as slides in a number of big name tech stocks following their earnings reports dominated the news flow and largely dictated the market's direction. ECONOMIC EVENTS: In the U.S., the FHFA home price index rose 0.4% to 222.8 in May, as expected. Existing home sales rose 3.2% to a 5.49M rate in June, better than the 0.9% increase that was expected. In Europe, the European Central Bank reportedly raised the cap on Greece's Emergency Liquidity Assistance by EUR900M to EUR90.4B, according to Bloomberg. COMPANY NEWS: The tech sector has been weak, headlined of course by a 5% pullback in shares of Apple (AAPL) after iPhone shipments in the just completed quarter and the company's sales forecast for the new quarter missed estimates. Adding to the negative tone in tech stocks, and contributing further to the decline in the Nasdaq, was the 3% drop seen in Microsoft (MSFT) shares after its quarterly report as well as Yahoo's (YHOO) 1% decline after its revenue outlook missed the consensus forecast... Shares of Boeing (BA) and Coca-Cola (KO) fared better than Dow peer Apple after each reported better than expected sales and profits, though neither stock was moving far from where they closed yesterday's trading. MAJOR MOVERS: Among the notable gainers was Thoratec (THOR), which rose 10% after the company agreed to be acquired by St. Jude Medical (STJ) for $3.4 billion in cash, or $63.50 per share. St. Jude shares advanced fractionally after the deal, which had been foreshadowed by media reports yesterday, was announced. Also higher following their earnings reports were Intuitive Surgical (ISRG), which gained 10%, Chipotle Mexican Grill (CMG), which advanced 8% and Whirlpool (WHR), which was up 6%. Among the noteworthy losers were a number of suppliers to Apple that declined in tandem with the tech giant after it reported a sequential drop in iPhone sales. Skyworks Solutions (SWKS), Cirrus Logic (CRUS), Qorvo (QRVO) and NXP Semiconductors (NXPI) were among the many semiconductor stocks that slid following Apple's report. Also sharply lower was antibody-based therapeutics maker XOMA (XOMA), which plunged more than 73% and was downgraded to Neutral at Piper Jaffray after a Phase III trial of its gevokizumab drug in patients with Behcet's disease uveitis did not meet its primary endpoint. INDEXES: Near midday, the Dow was down 82.22, or 0.46%, to 17,837.07, the Nasdaq was down 42.68, or 0.82%, to 5,165.44, and the S&P 500 was down 6.93, or 0.33%, to 2,112.28.
11:03 EDTXOMAXOMA downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:07 EDTXOMAOn The Fly: Pre-market Movers
Subscribe for More Information
08:31 EDTXOMAXOMA resumes, drops 63% after gevokizumab study misses primary endpoint
Subscribe for More Information
08:08 EDTXOMAXOMA to resume trading at 8:30 am EDT after trial misses endpoint
Shares of antibody-based therapeutics maker XOMA were halted for trading before the company announced that a Phase 3 study of gevokizumab in patients with Behçet's disease uveitis did not meet the primary endpoint of time to first acute ocular exacerbation. The stock is scheduled to resume quotation at 8:25 am EDT and resume trading at 8:30 am EDT, according to Nasdaq.
08:02 EDTXOMAXOMA Phase 3 EYEGUARD-B study of gevokizumab did not meet primary endpoint
XOMA announced the Phase 3 EYEGUARD-B study of gevokizumab in patients with Behçet's disease uveitis, run by its partner Servier, an independent French pharmaceutical research company driven by the pursuit of innovative drugs, did not meet the primary endpoint of time to first acute ocular exacerbation. "Although the study did not achieve its main objective, we did see signals of drug activity such as preserved visual acuity, less severe ocular exacerbations and a reduced incidence of reported macular edema in patients treated with gevokizumab," said Paul Rubin MD, Senior Vice President Research and Development and Chief Medical Officer. "We will continue to work closely with our partner, Servier, and uveitis experts to conduct a thorough analysis of the data to fully understand gevokizumab's impact on several clinically relevant endpoints." Gevokizumab appeared to be well tolerated in the trial. Adverse events were comparable between gevokizumab and placebo treated groups.
08:02 EDTXOMAXOMA Phase 3 EYEGUARD-B study of gevokizumab did not meet primary endpoint
Subscribe for More Information
07:59 EDTXOMAXOMA trading halted, pending news
Subscribe for More Information
06:36 EDTXOMAXOMA volatility elevated into expected release of Phase III data
XOMA August call option implied volatility is at 287, September is at 228, December is at 167; compared to its 52-week range of 71 to 299, suggesting large price movement into expected release Phase III data for gevokizumab in Behçet’s disease uveitis.
05:27 EDTXOMAStocks with implied volatility above IV index mean; XOMA AMZN
Subscribe for More Information
July 20, 2015
08:12 EDTXOMAXOMA volatility elevated into expected release of Phase III data
Subscribe for More Information
06:06 EDTXOMAStocks with implied volatility above IV index mean; XOMA TWTR
Subscribe for More Information
July 17, 2015
14:37 EDTPANWUCLA Health says 4.5M individuals' data possibly exposed in cyber attack
Subscribe for More Information
10:56 EDTPANWCVS investigates credit card breach at online photo unit, KrebsOnSecurity says
Subscribe for More Information
07:11 EDTPANWGigamon checks show continued momentum, says William Blair
Subscribe for More Information
05:55 EDTXOMAStocks with implied volatility above IV index mean; XOMA GMCR
Stocks with implied volatility above IV index mean; XOMA (XOMA) 295, Keurig Green Mountain (GMCR) 50 according to iVolatility.
July 16, 2015
10:00 EDTPANWOn The Fly: Analyst Initiation Summary
Subscribe for More Information
09:12 EDTPANWPalo Alto initiated with a Buy at Cleveland Research
Target $218.
08:36 EDTPANWFinjan Holdings files second lawsuit against Blue Coat
Finjan Holdings (FNJN) announced that its subsidiary, Finjan, Inc. has filed a second patent infringement lawsuit against Blue Coat Systems, alleging infringement of seven Finjan patents relating to new infringing Blue Coat products and services. The Complaint, filed July 15, 2015, in the U.S. District Court for the Northern District of California, alleges that Blue Coat's new products and services infringe seven Finjan patents. In particular, Finjan is asserting infringement of U.S. Patent Nos. 6,154,844; 6,965,968; 7,418,731; 8,079,086; 8,225,408; 8,566,580; 8,677,494; four of which are being asserted against Blue Coat for the first time. Finjan is seeking a jury trial; entry of judgment of direct and indirect infringement of certain claims of each of the asserted patents by Blue Coat; preliminary and permanent injunction against Blue Coat and its officers, among others, from infringing the asserted patents; and damages to be determined by a jury. This original case against Blue Coat will be proceeding to trial on July 20, 2015, with all six patents included in Finjan's first complaint against Blue Coat. Those patents include 6,804,780; 6,154,844; 7,418,731; 6,965,968; 7,058,822 and 7,647,633. The trial in the first case is expected to last for two weeks. Finjan has filed patent infringement lawsuits against FireEye (FEYE), Proofpoint, Sophos, Symantec (SYMC), and Palo Alto Networks (PANW) relating to, collectively, more than 20 patents in the Finjan portfolio.
05:51 EDTXOMAStocks with implied volatility movement; IDTI XOMA
Stocks with implied volatility movement; Integrated Device (IDTI) 64, XOMA (XOMA) 294 according to iVolatility.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use